Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Medical Device Experts

Articles with lock require a subscription to GLG News | Request a free trial
Ken PowellMarch 31, 2008
OTC Diagnostics Could Yield High Growth
Analysis of: The Outlook on Home, Direct Access Testing | www.aacc.org
Author: Ken Powell, President, Genesis Business Development
The current self-diagnostic market segment is approximately $7 billion and set to rapidly expand.  An attractive area of OTC diagnostics is Direct to Consumer (DTC) testing where the consumer initiates the testing process and obtains laboratory results without the need for a physician. ...
Patrick Joseph IgoeMarch 31, 2008
Patent Win Protects Eisai's Aricept Against Teva's Potential Generic Product Launch Via Preliminary Injunction
Analysis of: WSJ/Aricept Maker Wins Injunction In Patent Case | online.wsj.com
Author: Patrick Joseph Igoe, Life Sciences Patent Attorney, Independent IP Litigation Consultant
* As noted in the Wall Street Journal article, Aricept® is a blockbuster drug for the treatment of Alzheimer's disease.  And, as noted in Judge Ackerman's ruling, Aricept sales are a huge source of Eisai's revenue - "sales of Aricept® in the United States constitute 70% of Eisai’s...
Ken PowellMarch 28, 2008
Colon Cancer Company Seeks Strategic Business Alternatives
Analysis of: Exact Sciences explores sale | boston.bizjournals.com
Author: Ken Powell, President, Genesis Business Development
EXACT Science's (NADAQ: EXAS) non-invasive, DNA-based screening test for colon cancer could significantly increase the 90MM US adults over 50 that should participate in colorectal cancer screening.  Colon cancer is responsible for approximately 57,000 deaths in the US each year and...
March 24, 2008
Base Product in Baxter's Heparin Came from China!
Analysis of: Tainted Blood Drug to Face Import Tests | www.nytimes.com
Author: Joe Atkins, Chief Executive Officer, Medical Concepts & Innovations
1)  Baxter was producing 50% of the worlds heparin requirements, which provided short term anticoagulation for hemodialysis and various interventions for cardiovascular disease. 2)  The base product of heparin comes from porcine intestines. 3)  The base product of Baxter's heparin was...
March 24, 2008
Amgen Stock Set to Take a Fall!
Analysis of: Panel Seeks New Limits on Anemia Drugs | www.nytimes.com
Author: Joe Atkins, Chief Executive Officer, Medical Concepts & Innovations
1)  Amgen's and J&J's ESA products are going to continue to receive more black box warnings from the FDA. 2)  A federal Judge may force Amgen to accept a royalty from Roche, allowing their CERA ESA to come to market in the USA. 3)  Their is potential for more problems to arise,...
Patrick Joseph IgoeMarch 19, 2008
Amgen's EPO Patent Win At The Federal Circuit
Analysis of: WSJ/Court Sends Mircera Case Back To Trade Commission | online.wsj.com
Author: Patrick Joseph Igoe, Life Sciences Patent Attorney, Independent IP Litigation Consultant
(1) The US Court of Appeals for the Federal Circuit - in a complicated 22-page split Opinion earlier today Wed 19 Mar 2008 - provided Amgen another victory in its long patent battle(s) with Hoffmann-LaRoche. (2) Amgen's Aranesp® and EPOGEN® (each a prescription only product...
Ken PowellMarch 11, 2008
Healthcare and Molecular Diagnostics
Analysis of: Health-Care Equipment's Quickening Pulse | www.businessweek.com
Author: Ken Powell, President, Genesis Business Development
The healthcare industry continues to lead the market.  Year to date through Feb. 14, the S&P Health Care Equipment index slipped 0.5% vs. an 8% decline for the S&P 1500. During 2007, the healthcare index gained 10.4% to the broader market's climb of 3.6%.  According to S&P,...
February 28, 2008
Sterile Injectables Contract Manufacturing Market Outlook
Analysis of: Jubilant News for Hollister-Stier | www.contractpharma.com
Author: GLG Expert Contributor
As demand of the sterile injectables products grows, more and more contract manufacturers are evaluating this landscape as a potential opportunity for growth.  The major concerns in this market outlook are how complex is the technology, how much capacity is needed and will this technology be the...
Ken PowellFebruary 25, 2008
Molecular Diagnostics
Analysis of: Nanogen Patent Portfolio in Realtime PCR Strengthened | www.medcompare.com
Author: Ken Powell, President, Genesis Business Development
Nanogen's (Nasdaq: NGEN) two new US patents; No. 7,319,022 titled “Amplification Methods” and No. 7,297,495 titled “Hybridization-Triggered Fluorescent Detection Of Nucleic Acids” extend their portfolio of over 40 real-time PCR patents.  These patents play an important role in Nanogen's emerging...
Ken PowellFebruary 22, 2008
Ovarian Cancer Test
Analysis of: Blood test detects ovarian cancer early | today.reuters.com
Author: Ken Powell, President, Genesis Business Development
The early diagnosis of ovarian cancer is difficult and the disease is often not detected until it has reached an advanced stage.  A test that can diagnose Stage I/Stage II ovarian cancer could reduce the over 15,000 women that die from this form of cancer in the US each year.  Stage I and...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 Next41 to 50 of 122

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T09:45:16.440